Loading...
XSHE
002437
Market cap972mUSD
Jul 09, Last price  
2.96CNY
1D
2.07%
1Q
-18.68%
Jan 2017
-63.73%
IPO
3.17%
Name

HARBIN GLORIA PHARMACEUTICALS Co Ltd

Chart & Performance

D1W1MN
XSHE:002437 chart
P/E
17.51
P/S
3.09
EPS
0.17
Div Yield, %
—
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
-7.45%
Revenues
2.14b
-12.51%
275,610,229429,928,954575,448,365546,364,548711,030,3031,307,886,2451,905,823,9912,681,225,3072,983,728,1363,041,883,4535,481,339,8275,053,859,8933,054,949,2663,145,311,7033,145,311,7033,107,945,1603,107,945,1602,626,039,3062,440,732,0292,135,451,500
Net income
377m
+61.93%
105,950,873130,235,113154,713,039116,848,259164,769,969226,737,501443,770,006664,808,616716,648,322309,675,745125,893,642-2,661,773,270400,049,12945,042,02445,042,0300-291,328,827120,334,190232,759,460376,905,200
CFO
273m
-33.48%
52,260,50757,809,411170,815,046112,592,505128,606,944205,889,113453,020,477674,036,849702,047,2041,040,487,154651,795,3251,162,761,434610,365,81712,763,852274,181,021261,615,607274,175,284410,935,803273,355,513
Dividend
Jun 28, 20190.012 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.
URL
http://www.gloria.cc/
IPO date
Jun 23, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT